Picton Mahoney Asset Management Raises Stock Position in ADMA Biologics Inc (NASDAQ:ADMA)

Key Points

• Picton Mahoney Asset Management significantly increased its stake in ADMA Biologics by approximately 207,037.5%, acquiring a total of 132,568 shares, which are valued at around $2.6 million.
• Several other institutional investors also modified their holdings in ADMA, with hedge funds now owning 75.68% of the company's stock, indicating strong institutional interest.
• ADMA Biologics reported a net margin of 45.01% and revenue of $114.8 million for the latest quarter, showing a 40.2% increase compared to the same quarter last year.

Picton Mahoney Asset Management boosted its holdings in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 207,037.5% during the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 132,568 shares of the biotechnology company's stock after purchasing an additional 132,504 shares during the quarter. Picton Mahoney Asset Management owned about 0.06% of ADMA Biologics worth $2,629,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. JPMorgan Chase & Co. grew its holdings in ADMA Biologics by 272.5% in the fourth quarter. JPMorgan Chase & Co. now owns 767,265 shares of the biotechnology company's stock worth $13,159,000 after purchasing an additional 561,310 shares during the period. New York State Teachers Retirement System grew its holdings in ADMA Biologics by 96.2% in the first quarter. New York State Teachers Retirement System now owns 221,890 shares of the biotechnology company's stock worth $4,402,000 after purchasing an additional 108,800 shares during the period. GAMMA Investing LLC grew its holdings in ADMA Biologics by 251.6% in the first quarter. GAMMA Investing LLC now owns 6,589 shares of the biotechnology company's stock worth $131,000 after purchasing an additional 4,715 shares during the period. Concurrent Investment Advisors LLC purchased a new stake in ADMA Biologics in the first quarter worth about $201,000. Finally, Ameriprise Financial Inc. grew its holdings in ADMA Biologics by 14.1% in the fourth quarter. Ameriprise Financial Inc. now owns 715,672 shares of the biotechnology company's stock worth $12,274,000 after purchasing an additional 88,542 shares during the period. Hedge funds and other institutional investors own 75.68% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. Raymond James Financial upped their price objective on shares of ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a report on Thursday, May 8th. Wall Street Zen cut shares of ADMA Biologics from a "hold" rating to a "sell" rating in a report on Friday, May 9th.

Insiders Place Their Bets

In other news, Director Lawrence P. Guiheen sold 20,000 shares of the firm's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $20.96, for a total transaction of $419,200.00. Following the sale, the director directly owned 94,830 shares in the company, valued at $1,987,636.80. This trade represents a 17.42% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Steve Elms sold 194,749 shares of the firm's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $20.24, for a total transaction of $3,941,719.76. Following the sale, the director owned 87,330 shares in the company, valued at $1,767,559.20. The trade was a 69.04% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 464,621 shares of company stock worth $9,644,269. Company insiders own 3.50% of the company's stock.

ADMA Biologics Stock Up 3.4%

Shares of NASDAQ:ADMA traded up $0.63 during trading on Friday, reaching $19.33. 2,469,615 shares of the stock traded hands, compared to its average volume of 3,068,105. ADMA Biologics Inc has a 52-week low of $10.21 and a 52-week high of $25.67. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.36 and a current ratio of 6.58. The stock has a 50-day moving average of $18.83 and a two-hundred day moving average of $18.73. The stock has a market cap of $4.61 billion, a P/E ratio of 22.74 and a beta of 0.43.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.16 by ($0.02). ADMA Biologics had a return on equity of 47.16% and a net margin of 45.01%. The company had revenue of $114.80 million during the quarter, compared to analysts' expectations of $116.40 million. During the same quarter in the prior year, the business posted $0.08 EPS. The company's revenue for the quarter was up 40.2% compared to the same quarter last year. As a group, sell-side analysts expect that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.